CarePoint collaborates with GRAIL on early detection test for cancer

CarePoint Health in Hoboken announced new collaboration with GRAIL LLC, a health care company whose mission is to detect cancer early, when it can be cured.

Offering GRAIL’s Galleri test will enable CarePoint to enhance its comprehensive cancer care by incorporating a cutting-edge multicancer early detection test. This is part of CarePoint’s Center for Precision and Personalized Medicine, which aims to treat the origin of disease.

“As we strive to provide unparalleled care to the people of Hudson County, we’re proud to introduce cutting-edge multicancer early detection at our hospital. CarePoint’s mission to embrace innovation is not just about treating illness, but about empowering prevention and saving lives as soon as it is possible,” CarePoint Chief Medical Officer Dr. John Rimmer said.

To be eligible for the screenings, CarePoint patients must be established in one of CarePoint Health’s primary/specialty care practices, be at an elevated risk of cancer (such as individuals ages 50 or older), not be currently pregnant and not be undergoing active cancer treatment or have completed cancer treatment at least five years ago (excluding basal or squamous cell carcinoma of the skin).

“We have an opportunity to shift the cancer screening paradigm with multicancer early detection tests to screen for a ‘fingerprint’ of the deadliest cancers before they become symptomatic, including those without recommended screening tests today,” Dr. Jeffrey Venstrom, chief medical officer at GRAIL, said. “By offering the Galleri test to the patients of Hudson County, CarePoint Health is providing patients with the best chance to screen for, and ultimately diagnose many types of cancer early. We are pleased to share in their commitment to elevated patient care.”

The Galleri test, available by prescription only, is the first-of-its-kind clinically validated MCED test capable of detecting a shared cancer signal across more than 50 types of cancers using a simple blood draw. This revolutionary blood-based approach is intended to be used in addition to recommended single cancer screenings.

“As far as modern medicine goes, this is our best shot at increasing our chances of beating cancer early, and we are so proud to be able to provide this service to our patients,” CarePoint chief of staff and Vice President of Marketing and Patient Strategy Justin Drew said.

Following a positive Galleri test result, CarePoint will use this technology to support patients and providers throughout the diagnostic journey. Plans to enhance patient experience and outcomes include standardizing patient and provider education, developing evidence-based diagnostic pathways and facilitating timely evaluations.